3 March 2016 - Currently marketed in the U.S. as Adynovate [Antihemophilic Factor (Recombinant), PEGylated], Adynovi is an innovative recombinant Factor VIII treatment designed to offer simple, twice-weekly dosing.

For more details, go to: http://newsroom.baxalta.com/press-releases/press-release-details/2016/Baxalta-Submits-Marketing-Authorization-Application-to-the-European-Medicines-Agency-for-ADYNOVI-for-Treatment-of-Hemophilia-A-Patients/default.aspx